FIELD: pharmaceutics.
SUBSTANCE: group of inventions relates to humanised antibodies and their fragments, which specifically bind a polypeptide containing peptide-6, denoted by SEQ ID NO: 15, which is a peptide derived from HSP65. More specifically invention relates to compositions, methods and use thereof for treating immune disorders. Further, group of inventions includes combined compositions and kit combining humanised antibodies and at least one anti-inflammatory agent.
EFFECT: use of humanised antibodies according to invention enables to modulate balance of Th1/Th2 cytokines.
29 cl, 31 dwg, 13 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| ANTI HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN (IL1RAP) ANTIBODIES AND USES THEREOF | 2015 |
|
RU2710787C2 |
| METHODS FOR TREATMENT USING ANTI-IL-17A ANTIBODIES | 2016 |
|
RU2754683C2 |
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| ANTI-LAG-3 ANTIBODIES | 2016 |
|
RU2760582C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
| ANTI-TFR ANTIBODIES AND USE THEREOF IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS | 2016 |
|
RU2737637C2 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| ANTIBODIES AGAINST SIGLEC-15 AND THEIR APPLICATION METHODS | 2017 |
|
RU2759334C2 |
